Taking into account the efficacy results of combined TT in metastatic melanoma patients with BRAF mutation and the clinical need to improve the outcomes of adjuvant therapy in melanoma, studies have been carried out to establish whether TT in an adjuvant setting would improve outcomes in BRAFV600-mutant patients with resected stage III and IV melanoma. The gene discussed is BRAF; the disease is melanoma.